Aardvark Therapeutics, Inc. (AARD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
5.96 USD
-1.64
(-21.579%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.96 0.00 (-0.001%) ⇩ (July 13, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:52 a.m. EDT
The investment case for Aardvark Therapeutics has collapsed. The company is actively exiting its Prader-Willi drug development efforts and paused late-stage trials due to cardiac findings, signaling a fundamental failure in its core pipeline. Financially, the picture is dire: negative earnings, negative free cash flow, and a return on equity of nearly -60%. While the balance sheet currently holds cash, the lack of revenue growth and the cessation of key clinical programs suggest the business model is failing. The stock has lost roughly 38% of its value over the last year, and the market is pricing in further distress. Options activity confirms this pessimism, with heavy put writing at the $2.50 level suggesting traders expect the price to drop significantly lower. There is no catalyst for a turnaround visible in the data; the company is effectively a shell waiting for a potential acquisition or liquidation, making it a dangerous hold for any investor. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.254983 |
| AutoTheta | 0.263666 |
| AutoETS | 0.264206 |
| AutoARIMA | 0.264211 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.232 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.386 |
| Market Cap | 130,025,648 |
| Forward P/E | -1.84 |
| Website | https://aardvarktherapeutics.com |
As of July 11, 2026, 3:52 a.m. EDT: Speculators are positioning for a sharp decline. Put open interest is heavily concentrated at the $2.50 strike, acting as a massive floor for downside protection, while call activity is negligible and focused only on immediate expiration. The implied volatility skew shows a massive premium for downside protection compared to upside potential, indicating a 'bear put' sentiment where traders are betting on further deterioration rather than recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.37241948 |
| Address1 | 4,370 La Jolla Village Drive |
| Address2 | Suite 1050 |
| All Time High | 19.58 |
| All Time Low | 3.35 |
| Ask | 7.53 |
| Ask Size | 2 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 765,310 |
| Average Daily Volume3 Month | 261,998 |
| Average Volume | 261,998 |
| Average Volume10Days | 765,310 |
| Bid | 5.57 |
| Bid Size | 2 |
| Book Value | 3.987 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.96 |
| Current Ratio | 8.064 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 7.9176 |
| Day Low | 5.885 |
| Debt To Equity | 0.386 |
| Display Name | Aardvark Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -74,677,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.524 |
| Enterprise Value | 39,161,656 |
| Eps Current Year | -3.65111 |
| Eps Forward | -3.2375 |
| Eps Trailing Twelve Months | -3.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7928 |
| Fifty Day Average Change | 1.1672001 |
| Fifty Day Average Change Percent | 0.24353199 |
| Fifty Two Week Change Percent | -37.241947 |
| Fifty Two Week High | 17.94 |
| Fifty Two Week High Change | -11.9800005 |
| Fifty Two Week High Change Percent | -0.6677815 |
| Fifty Two Week Low | 3.35 |
| Fifty Two Week Low Change | 2.6100001 |
| Fifty Two Week Low Change Percent | 0.77910453 |
| Fifty Two Week Range | 3.35 - 17.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,739,457,000,000 |
| Float Shares | 10,910,374 |
| Forward Eps | -3.2375 |
| Forward P E | -1.8409266 |
| Free Cashflow | -34,437,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16096 |
| Held Percent Institutions | 0.56234 |
| Implied Shares Outstanding | 21,816,385 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-02-13 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. |
| Long Name | Aardvark Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 130,025,648 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_614979892 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -69,869,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 167,113,509 |
| Number Of Analyst Opinions | 9 |
| Open | 7.35 |
| Operating Cashflow | -61,653,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 225 7696 |
| Post Market Change | -0.00069999695 |
| Post Market Change Percent | -0.0117449155 |
| Post Market Price | 5.9593 |
| Post Market Time | 1,783,986,533 |
| Previous Close | 7.6 |
| Price Eps Current Year | -1.6323804 |
| Price Hint | 2 |
| Price To Book | 1.4948583 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.859 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.25 |
| Region | US |
| Regular Market Change | -1.64 |
| Regular Market Change Percent | -21.5789 |
| Regular Market Day High | 7.9176 |
| Regular Market Day Low | 5.885 |
| Regular Market Day Range | 5.885 - 7.9176 |
| Regular Market Open | 7.35 |
| Regular Market Previous Close | 7.6 |
| Regular Market Price | 5.96 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 651,802 |
| Return On Assets | -0.36539 |
| Return On Equity | -0.58794 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,816,385 |
| Shares Percent Shares Out | 0.0242 |
| Shares Short | 528,265 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 987,661 |
| Short Name | Aardvark Therapeutics, Inc. |
| Short Percent Of Float | 0.0367 |
| Short Ratio | 2.4 |
| Source Interval | 15 |
| State | CA |
| Symbol | AARD |
| Target High Price | 45.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 15.44444 |
| Target Median Price | 7.0 |
| Total Cash | 91,200,000 |
| Total Cash Per Share | 4.18 |
| Total Debt | 336,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.18895 |
| Two Hundred Day Average Change | -3.2289495 |
| Two Hundred Day Average Change Percent | -0.35139486 |
| Type Disp | Equity |
| Volume | 651,802 |
| Website | https://aardvarktherapeutics.com |
| Zip | 92,122 |